

Dabrafenib-trametinib ROAR, NCI-MATCH (subprotocol H)

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Dabrafenib-trametinib ROAR, NCI-MATCH (subprotocol H)

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: dMMR/MSI-H solid tumour
Therapeutic Indication: Adult and paediatric patients ≥ 1 year of age with unresectable or metastatic solid tumours with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Experimental Arm: Dabrafenib-trametinib
Control Arm: Single arm



